

Revisiting the Performance Dynamics of Fallen Angels

- We revisit the performance dynamics of fallen angels over the past five years given two important dynamics in the high yield market: the 'hunt for yield' by investors as a result of the low rate environment and the decline in the relative supply of fallen angels.
- We find that the increased demand for high yield bonds and simultaneous decline in the supply of fallen angels have had a pronounced effect on the pattern of mean reversion in performance that we have documented previously.
- The magnitude of the underperformance experienced by fallen angels since 2010 prior to the downgrade announcement was about one fifth of the underperformance found in earlier years, and consequently on average they have exhibited essentially no mean reversion following their downgrade.
- Despite the change in fallen angels' dynamics in recent years, the simple rule-based strategy we developed in 2010 in order to capitalize on the fallen angels phenomenon ('3-Month Reversal') continued to outperform a portfolio of high yield peer bonds by about 3.5%/year.
- The difference between the behaviour of fallen angels in aggregate and the performance of the '3-Month Reversal' strategy reflects the fact that the strategy does not invest in fallen angels indiscriminately but employs time and price criteria.

Arik Ben Dor
+1 212 526 7713
arik.bendor@barclays.com
BCI, US

Jason Xu
+1 212 526 6782
jason.xu@barclays.com
BCI, US

www.barclays.com

Do Fallen Angels Still Exhibit Mean Reversion?

Several years ago, we conducted a detailed analysis of the characteristics and price dynamics of fallen angels using a comprehensive sample spanning more than 20 years and 1,400 bonds that migrated from investment grade to non-investment grade status.¹ We found that investors began to liquidate the soon-to-become fallen angels prior to the actual rating change, a process that peaked about three months after the downgrade. As the selling intensity dissipated, price declines reversed, and fallen angels outperformed high yield peers with similar characteristics for up to two years after the downgrade. Furthermore, the price recovery by an individual issuer was inversely related to the magnitude of its initial underperformance. We presented a simple rule-based strategy that total-return managers could employ to exploit these price patterns, which generated an average outperformance of 8.5%/year over high yield peers with information ratios in excess of one. The outperformance was not confined to a specific period but was evident throughout the sample. However, the study, as well as a follow-up analysis of fallen angels in the Euro-market, showed that the degree of initial price drop and the subsequent mean reversion was affected by the imbalance between supply (the volume of fallen angels) and demand (the capital available to acquire them).²

Over the past several years, U.S. credit markets have experienced two important dynamics related to the potential demand-supply imbalance. First, as Figure 1 shows, the annual volume of fallen angels since 2010 represented only 1.4% to 3.4% of the total size of the high yield market, as opposed to an average of 8% (median of 6.1%) in the earlier period (1990 – 2009) as reported in Ben Dor and Xu (2010). The sharp decline mostly reflected the increase in the overall size of the high yield market as opposed to a drop in the market value of downgraded issuers.³ Hence, the market capacity to absorb the supply of fallen angels has improved. Furthermore, the low rate environment resulted in a hunt for yield by investors and increased demand for high yield securities. This demand resulted in an unprecedented issuance of high yield debt totalling about three times the average in earlier years (last column) but may have also spilled over to fallen angels as a secondary source of supply.

FIGURE 1
Supply of Fallen Angels and Demand for High Yield Securities

Year	Number of Fallen Angels Issuers	Market Value of FA Bonds (\$bn)	Market Value of FA as % of High-Yield Index	Primary High-Yield Issuance (\$bn)
Ben Dor and Xu (2010): Annual Results 1990 - 2009				
Average	22.1	26.7	8.0%	99.1
Median	16.5	16.3	6.1%	102.1
2010	7.0	16.1	2.0%	263.7
2011	9.0	13.0	1.4%	226.2
2012	14.0	27.3	2.7%	329.6
2013	12.0	40.1	3.4%	334.1
2014	16.0	29.3	2.2%	311.7

Note: The data on primary issuance of high-yield debt is based on SIFMA (Securities Industry and Financial Markets Association) figures. Source: SIFMA, Barclays Research


¹ Ben Dor, A. and J. Xu., *Fallen Angels: Characteristics, Performance, and Implications for Investors*, Barclays Capital, December 2010.

² See Ben Dor, Eisenthal-Berkovitz, and Xu (2012), which examined the performance stability of fallen angels over time and across geographical markets, and addressed various implementation issues resulting from the unique characteristics of fallen angels.

³ The size of the high yield market (bonds included in the Barclays High Yield Index) was one-tenth of the size of the investment grade universe in 1990 (\$52bn vs. \$520bn, respectively) whereas in 2014 the ratio increased to 34% (\$1.3trn vs. \$3.9trn, respectively).

To what extent did the patterns documented in Figure 1 affect the price dynamics of fallen angels? Figure 2 plots the cumulative relative return (over issuer-matched peer groups) of fallen angels during a three-year window starting four quarters prior to the downgrade to high yield status. The chart shows that in the period covered in the study in Ben Dor and Xu (2010), fallen angels underperformed peers by 15.09% in the downgrade month and preceding year, followed by a sharp reversal in the next two years when they outperformed high yield peers by 6.38% on average. In contrast, over the past few years, fallen angels exhibited very mild mean reversion, declining only by a total of 2.89%, (of which 2.12% occurred in the rating change month), and then essentially remaining flat (outperforming peers by only 47bp over the following 24 months).

FIGURE 2
Cumulative Performance of Fallen Angels over Peers around Downgrade Month



Note: The figure reports the performance of issuers by quarter relative to the downgrade month (defined as quarter zero). The return of each issuer is over the contemporaneous return of a peer group with similar characteristics ('Relative returns') based on industry (financials, industrials, and utilities), credit quality (A and higher, Baa, Ba, B, and Caa and lower), and maturity (up to ten years and above ten years). Cumulative relative returns were calculated by first averaging issuers' relative returns by month and then cumulating them since the beginning of the analysis window. Cumulative relative returns are reported as of the end of each quarter. Source: Barclays Research

The results in Figure 2 are consistent with the idea that the increased demand for high yield securities alongside the decline in the (relative) supply of fallen angels substantially limited the scope of the price decline until the downgrade to high yield, which in turn led to a muted reversal in subsequent quarters.

To formally test this explanation, the cumulative (relative) return of each issuer over the twelve-month window centred on the downgrade is separated into two parts, (from five months prior to the downgrade month until the end of the rating change month, and the six months following the downgrade month) representing the initial decline and subsequent reversal. This allows us to capture the relation we posit between the degree of initial price drop and magnitude of price reversal. Figure 3 presents the results of two regressions linking the performance in the first period to the aggregate supply of fallen angels and other market-wide, and issuer specific characteristics, and performance in the second period with the market-wide demand for high-yield debt in addition to the cumulative return in the first period.

FIGURE 3

The Determinants of Fallen Angels Pre- and Post Downgrade Performance

Dep. Variables	Cum. RelRet (month -5 to 0)		Cum. RelRet (month 1 to 6)	
	Coef.	t-stats	Coef.	t-stats
Intercept	2.31	0.27	4.49	1.73
FA Supply (% of HY trailing 12m)	-0.34	-2.80		
HY OAS (avg. trailing 12m)	-0.57	-1.96		
MV of DG Issuer (in log)	0.08	0.14		
Notch of DG	-3.36	-6.68		
Financial Issuers?	-1.23	-0.60		
Utility Issuers?	1.44	0.71		
Cum. RelRet (month -5 to 0)			-0.39	-6.59
HY Issuance (% of HY trailing 12m)			-0.17	-2.13
# of Obs	492		492	
Adj. RSq	11%		9%	

Note: Based on data between 1990 and 2014. Source: Barclays Research

The results of the first regression confirm that the initial price decline is affected by the overall supply of fallen angels in addition to the state of the high yield market (proxied by its OAS level) and the bond characteristics (such as severity of the downgrade and industry). The estimated coefficient for FA supply suggests that the difference between the long-term average supply (8%) and that in recent years (2-3%) should have decreased the initial underperformance by 1.6-2% with the decline in market spread and severity of downgrades accounting for another 2-2.5%. Hence, over half of the change in the recent underperformance of fallen angels was not due to the systematic factors we controlled for.

The second regression illustrates the mean reversion pattern as the post-downgrade period performance is negatively linked to the size of the performance in the first period with a significant t-statistic of 6.59. In addition, it shows the effect of the demand for high yield securities. An increase of 10% in primary issuance was associated with a decline of 170bp in overall performance over the first six months after the downgrade. Collectively, the results in Figure 3 are consistent with the notion that the effect of the decline in fallen angels supply and simultaneous increase in demand for high yield securities limited both the initial price decline and the ensuing recovery.

How did the change in performance pattern documented in Figure 2 affect the profitability of the rule-based strategies we presented in the past in order to benefit from fallen angels' behaviour? Figure 4 compares the performances of the 'Buy All' and '3-Month Reversal' strategies during the period covered in Ben Dor and Xu (2010) to those between 2010 and 2014. The "Buy All" portfolio was meant to capture the collective performance of fallen angels, and therefore acquired all bonds at the end of the downgrade month and held them for up to 24 months.⁴ Since 2010, the "Buy All" portfolio included over 120 individual issuers (notice that some were downgraded in 2009 or 2008). In contrast, the "3-Month Reversal" purchased only the subset of bonds that were trading at spreads of at least 40bp

⁴ See Ben Dor and Xu (2010) for a detailed description of the 'Buy All' and '3-Month Reversal'.

over high yield peers three months after downgrade (once forced selling had on average subsided). In addition, bonds were sold from this portfolio prior to the end of the holding period if their relative spread to peers declined to zero. Since 2010, the “3-Month Reversal” portfolio included 33 individual issuers.

Looking first at the ‘Buy All’ portfolio (which includes all fallen angels once they transition to high yield and up to two years thereafter) reveals a sharp decline in the profitability of the strategy consistent with the results in Figure 2. The portfolio generated an average return of 1.07%/month in the first period compared with only 0.78%/month recently, while the performance of the peer benchmark was unchanged (0.75% and 0.76%/month respectively). Thus, over the past couple of years, fallen angels *in aggregate* did not materially differ from originally issued high yield bonds in terms of performance (and risk).

FIGURE 4

The Performance of Fallen Angels Strategy Portfolios

	'Buy All'			'3-Month Reversal'			High-Yield Index
	Portfolio	Peer Group	Ret. over Peer Group	Portfolio	Peer Group	Ret. over Peer Group	
Jan. 1991 - Jun. 2010 (Ben Dor and Xu 2010 study)							
Average (Monthly)	1.07%	0.76%	0.31%	1.62%	0.84%	0.78%	0.81%
Volatility (Monthly)	2.79%	2.16%	1.68%	3.99%	2.31%	2.63%	2.68%
Sharpe/Inf. Ratio (Ann.)	0.90	0.68	0.64	1.12	0.76	1.03	0.61
% of Positive Ret. Months	73%	75%	58%	75%	76%	63%	76%
% Invested in Fallen Angels	98%			69%			
Jul. 2010 - Dec. 2014							
Average (Monthly)	0.78%	0.75%	0.03%	1.11%	0.80%	0.31%	0.74%
Volatility (Monthly)	1.67%	1.65%	0.84%	1.85%	1.62%	0.88%	1.78%
Sharpe/Inf. Ratio (Ann.)	1.59	1.54	0.14	2.06	1.67	1.23	1.40
% of Positive Ret. Months	76%	74%	59%	74%	74%	65%	74%
% Invested in Fallen Angels	100%			55%			

Note: The returns for the portfolios' peer group were computed as the equal-weighted performances of the individual bonds' peer groups (as explained in Figure 2). Sharpe Ratio was calculated using 1m Libor. Information ratio is the ratio of average and standard deviation of relative returns. Source: Barclays Research

In contrast, the results for the ‘3-Month Reversal’ strategy (which only buys into fallen angels three months after the downgrade and only if they widened sufficiently) indicate that the strategy still generated significant outperformance over the peer group (1.11% vs. 0.80%/month, respectively). However, the decline in the mean-reversion dynamic of fallen angels is apparent as the outperformance was cut by more than half compared with the initial study period (1990 – 6/2010) when the difference was 0.78%/month. Notice that the percentage of the portfolio that was actually invested in fallen angels decreased as well from 69% to 55% but this actually decreased the outperformance gap between the two periods, since the long-term performance of fallen angels was higher than in recent years.⁵ Notice also that because of the large decline in market volatility, the Sharpe ratios of both the ‘3-Month Reversal’ portfolio and portfolio of peers (as well as the high-yield Index) almost doubled.

⁵ In order to maintain portfolio diversification, the maximum weight to any individual bond was capped at 10%. As a result, the portfolio was not fully invested in fallen angels anytime there were fewer than 20 eligible bonds (representing 20 individual issuers), and the remainder was allocated to the peer benchmark.

Conclusions

The performance of fallen angels over the past several years has been substantially different compared with their long-term behaviour during the period 1990–2009. The large underperformance prior to the downgrade, which was followed by a strong reversal starting about three months after the rating change as the selling abated, all but disappeared. While a significant part of the change can be attributed to the combined effect of the increased demand for high yield securities and decline in the *relative* supply of fallen angels, it did not seem to fully explain the new dynamic. However, the ‘3-Month Reversal’ strategy we first introduced in Ben Dor and Xu (2010) still generated superior performance relative to peer high yield bonds as a result of its bond selection criteria as opposed to investing in all fallen angels indiscriminately. Specifically, the ‘Buy All’ portfolio included more than 120 issuers since 2010, the ‘3-Month Reversal’ included only 33.

References

Ben Dor, A. and J. Xu., *Fallen Angels: Characteristics, Performance, and Implications for Investors*, Barclays Capital, December 14, 2010.

Ben Dor, A., Y. Eisenthal-Berkovitz, and J. Xu., *Fallen Angels: Capacity, Transaction Costs, and the Bond-CDS Basis*, Barclays Capital, February 29, 2012.

Analyst Certification

We, Arik Ben Dor and Jason Xu, hereby certify (1) that the views expressed in this research report accurately reflect our personal views about any or all of the subject securities or issuers referred to in this research report and (2) no part of our compensation was, is or will be directly or indirectly related to the specific recommendations or views expressed in this research report.

Important Disclosures:

Barclays Research is a part of the Investment Bank of Barclays Bank PLC and its affiliates (collectively and each individually, "Barclays"). For current important disclosures regarding companies that are the subject of this research report, please send a written request to: Barclays Research Compliance, 745 Seventh Avenue, 14th Floor, New York, NY 10019 or refer to <http://publicresearch.barclays.com> or call 212-526-1072.

Barclays Capital Inc. and/or one of its affiliates does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that Barclays may have a conflict of interest that could affect the objectivity of this report. Barclays Capital Inc. and/or one of its affiliates regularly trades, generally deals as principal and generally provides liquidity (as market maker or otherwise) in the debt securities that are the subject of this research report (and related derivatives thereof). Barclays trading desks may have either a long and / or short position in such securities, other financial instruments and / or derivatives, which may pose a conflict with the interests of investing customers. Where permitted and subject to appropriate information barrier restrictions, Barclays fixed income research analysts regularly interact with its trading desk personnel regarding current market conditions and prices. Barclays fixed income research analysts receive compensation based on various factors including, but not limited to, the quality of their work, the overall performance of the firm (including the profitability of the Investment Banking Department), the profitability and revenues of the Markets business and the potential interest of the firm's investing clients in research with respect to the asset class covered by the analyst. To the extent that any historical pricing information was obtained from Barclays trading desks, the firm makes no representation that it is accurate or complete. All levels, prices and spreads are historical and do not represent current market levels, prices or spreads, some or all of which may have changed since the publication of this document. The Investment Bank's Research Department produces various types of research including, but not limited to, fundamental analysis, equity-linked analysis, quantitative analysis, and trade ideas. Recommendations contained in one type of research may differ from recommendations contained in other types of research, whether as a result of differing time horizons, methodologies, or otherwise. Unless otherwise indicated, trade ideas contained herein are provided as of the date of this report and are subject to change without notice due to changes in prices. In order to access Barclays Statement regarding Research Dissemination Policies and Procedures, please refer to <https://live.barcap.com/publiccp/RSR/nyfipubs/disclaimer/disclaimer-research-dissemination.html>. In order to access Barclays Research Conflict Management Policy Statement, please refer to: <https://live.barcap.com/publiccp/RSR/nyfipubs/disclaimer/disclaimer-conflict-management.html>.

Barclays legal entities involved in publishing research:

Barclays Bank PLC (Barclays, UK)
Barclays Capital Inc. (BCI, US)
Barclays Securities Japan Limited (BSJL, Japan)
Barclays Bank PLC, Tokyo branch (Barclays Bank, Japan)
Barclays Bank PLC, Hong Kong branch (Barclays Bank, Hong Kong)
Barclays Capital Canada Inc. (BCCI, Canada)
Absa Bank Limited (Absa, South Africa)
Barclays Bank Mexico, S.A. (BBMX, Mexico)
Barclays Capital Securities Taiwan Limited (BCSTW, Taiwan)
Barclays Capital Securities Limited (BCSL, South Korea)
Barclays Securities (India) Private Limited (BSIPL, India)
Barclays Bank PLC, India branch (Barclays Bank, India)
Barclays Bank PLC, Singapore branch (Barclays Bank, Singapore)
Barclays Bank PLC Australia branch (Barclays Bank, Australia)

Disclaimer:

This publication has been produced by the Investment Bank of Barclays Bank PLC and/or one or more of its affiliates (collectively and each individually, "Barclays"). It has been distributed by one or more Barclays legal entities that are a part of the Investment Bank as provided below. It is provided to our clients for information purposes only, and Barclays makes no express or implied warranties, and expressly disclaims all warranties of merchantability or fitness for a particular purpose or use with respect to any data included in this publication. Barclays will not treat unauthorized recipients of this report as its clients. Prices shown are indicative and Barclays is not offering to buy or sell or soliciting offers to buy or sell any financial instrument.

Without limiting any of the foregoing and to the extent permitted by law, in no event shall Barclays, nor any affiliate, nor any of their respective officers, directors, partners, or employees have any liability for (a) any special, punitive, indirect, or consequential damages; or (b) any lost profits, lost revenue, loss of anticipated savings or loss of opportunity or other financial loss, even if notified of the possibility of such damages, arising from any use of this publication or its contents.

Other than disclosures relating to Barclays, the information contained in this publication has been obtained from sources that Barclays Research believes to be reliable, but Barclays does not represent or warrant that it is accurate or complete. Barclays is not responsible for, and makes no warranties whatsoever as to, the content of any third-party web site accessed via a hyperlink in this publication and such information is not incorporated by reference.

The views in this publication are those of the author(s) and are subject to change, and Barclays has no obligation to update its opinions or the information in this publication. The analyst recommendations in this publication reflect solely and exclusively those of the author(s), and such opinions were prepared independently of any other interests, including those of Barclays and/or its affiliates. This publication does not constitute personal investment advice or take into account the individual financial circumstances or objectives of the clients who receive it. The securities discussed herein may not be suitable for all investors. Barclays recommends that investors independently evaluate each issuer, security or instrument discussed herein and consult any independent advisors they believe necessary. The value of and income from any investment may fluctuate from day to day as a result of changes in relevant economic markets (including changes in market liquidity). The information herein is not intended to predict actual results, which may differ substantially from those reflected. Past performance is not necessarily indicative of future results.

This material has been issued and approved for distribution in the UK and European Economic Area by Barclays Bank PLC. It is being made available primarily to persons who are investment professionals as that term is defined in Article 19 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005. It is directed at, and therefore should only be relied upon by, persons who have professional experience in matters relating to investments. The investments to which it relates are available only to such persons and will be entered into only with such persons. Barclays Bank PLC is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority and is a member of the London Stock Exchange.

The Investment Bank of Barclays Bank PLC undertakes U.S. securities business in the name of its wholly owned subsidiary Barclays Capital Inc., a FINRA and SIPC member. Barclays Capital Inc., a U.S. registered broker/dealer, is distributing this material in the United States and, in connection therewith, accepts responsibility for its contents. Any U.S. person wishing to effect a transaction in any security discussed herein should do so only by contacting a representative of Barclays Capital Inc. in the U.S. at 745 Seventh Avenue, New York, New York 10019.

Non-U.S. persons should contact and execute transactions through a Barclays Bank PLC branch or affiliate in their home jurisdiction unless local regulations permit otherwise.

Barclays Bank PLC, Paris Branch (registered in France under Paris RCS number 381 066 281) is regulated by the Autorité des marchés financiers and the Autorité de contrôle prudentiel. Registered office 34/36 Avenue de Friedland 75008 Paris.

This material is distributed in Canada by Barclays Capital Canada Inc., a registered investment dealer, a Dealer Member of IIROC (www.iiroc.ca), and a Member of the Canadian Investor Protection Fund (CIPF).

Subject to the conditions of this publication as set out above, the Corporate & Investment Banking Division of Absa Bank Limited, an authorised financial services provider (Registration No.: 1986/004794/06. Registered Credit Provider Reg No NCRCP7), is distributing this material in South Africa. Absa Bank Limited is regulated by the South African Reserve Bank. This publication is not, nor is it intended to be, advice as defined and/or contemplated in the (South African) Financial Advisory and Intermediary Services Act, 37 of 2002, or any other financial, investment, trading, tax, legal, accounting, retirement, actuarial or other professional advice or service whatsoever. Any South African person or entity wishing to effect a transaction in any security discussed herein should do so only by contacting a representative of the Corporate & Investment Banking Division of Absa Bank Limited in South Africa, 15 Alice Lane, Sandton, Johannesburg, Gauteng 2196. Absa Bank Limited is a member of the Barclays group.

In Japan, foreign exchange research reports are prepared and distributed by Barclays Bank PLC Tokyo Branch. Other research reports are distributed to institutional investors in Japan by Barclays Securities Japan Limited. Barclays Securities Japan Limited is a joint-stock company incorporated in Japan with registered office of 6-10-1 Roppongi, Minato-ku, Tokyo 106-6131, Japan. It is a subsidiary of Barclays Bank PLC and a registered financial instruments firm regulated by the Financial Services Agency of Japan. Registered Number: Kanto Zaimukyokuchō (kinsho) No. 143.

Barclays Bank PLC, Hong Kong Branch is distributing this material in Hong Kong as an authorised institution regulated by the Hong Kong Monetary Authority. Registered Office: 41/F, Cheung Kong Center, 2 Queen's Road Central, Hong Kong.

Information on securities/instruments that trade in Taiwan or written by a Taiwan-based research analyst is distributed by Barclays Capital Securities Taiwan Limited to its clients. The material on securities/instruments not traded in Taiwan is not to be construed as 'recommendation' in Taiwan. Barclays Capital Securities Taiwan Limited does not accept orders from clients to trade in such securities. This material may not be distributed to the public media or used by the public media without prior written consent of Barclays.

This material is distributed in South Korea by Barclays Capital Securities Limited, Seoul Branch.

All Indian securities related research and other equity research are distributed in India by Barclays Securities (India) Private Limited (BSIPL). BSIPL is a company incorporated under the Companies Act, 1956 having CIN U67120MH2006PTC161063. BSIPL is registered and regulated by the Securities and Exchange Board of India (SEBI) as a Portfolio Manager INP000002585; Stock Broker/Trading and Clearing Member: National Stock Exchange of India Limited (NSE) Capital Market INB231292732, NSE Futures & Options INF231292732, NSE Currency derivatives INE231450334, Bombay Stock Exchange Limited (BSE) Capital Market INB011292738, BSE Futures & Options INF011292738; Merchant Banker: INM000011195; Depository Participant (DP) with the National Securities & Depositories Limited (NSDL): DP ID: IN-DP-NSDL-299-2008; Investment Adviser: INA000000391. The registered office of BSIPL is at 208, Ceejay House, Shivsagar Estate, Dr. A. Besant Road, Worli, Mumbai – 400 018, India. Telephone No: +91 22 67196000. Fax number: +91 22 67196100. Any other reports are distributed in India by Barclays Bank PLC, India Branch.

Barclays Bank PLC Frankfurt Branch distributes this material in Germany under the supervision of Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin).

This material is distributed in Malaysia by Barclays Capital Markets Malaysia Sdn Bhd.

This material is distributed in Brazil by Banco Barclays S.A.

This material is distributed in Mexico by Barclays Bank Mexico, S.A.

Barclays Bank PLC in the Dubai International Financial Centre (Registered No. 0060) is regulated by the Dubai Financial Services Authority (DFSA). Principal place of business in the Dubai International Financial Centre: The Gate Village, Building 4, Level 4, PO Box 506504, Dubai, United Arab Emirates. Barclays Bank PLC-DIFC Branch, may only undertake the financial services activities that fall within the scope of its existing DFSA licence. Related financial products or services are only available to Professional Clients, as defined by the Dubai Financial Services Authority.

Barclays Bank PLC in the UAE is regulated by the Central Bank of the UAE and is licensed to conduct business activities as a branch of a commercial bank incorporated outside the UAE in Dubai (Licence No.: 13/1844/2008, Registered Office: Building No. 6, Burj Dubai Business Hub, Sheikh Zayed Road, Dubai City) and Abu Dhabi (Licence No.: 13/952/2008, Registered Office: Al Jazira Towers, Hamdan Street, PO Box 2734, Abu Dhabi).

Barclays Bank PLC in the Qatar Financial Centre (Registered No. 00018) is authorised by the Qatar Financial Centre Regulatory Authority (QFCRA). Barclays Bank PLC-QFC Branch may only undertake the regulated activities that fall within the scope of its existing QFCRA licence. Principal place of business in Qatar: Qatar Financial Centre, Office 1002, 10th Floor, QFC Tower, Diplomatic Area, West Bay, PO Box 15891, Doha, Qatar. Related financial products or services are only available to Business Customers as defined by the Qatar Financial Centre Regulatory Authority.

This material is distributed in the UAE (including the Dubai International Financial Centre) and Qatar by Barclays Bank PLC.

This material is distributed in Russia by OOO Barclays Capital, affiliated company of Barclays Bank PLC, registered and regulated in Russia by the FSFM. Broker License #177-11850-100000; Dealer License #177-11855-010000. Registered address in Russia: 125047 Moscow, 1st Tverskaya-Yamskaya str. 21.

This material is distributed in Singapore by the Singapore branch of Barclays Bank PLC, a bank licensed in Singapore by the Monetary Authority of Singapore. For matters in connection with this report, recipients in Singapore may contact the Singapore branch of Barclays Bank PLC, whose registered address is One Raffles Quay Level 28, South Tower, Singapore 048583.

Barclays Bank PLC, Australia Branch (ARBN 062 449 585, AFSL 246617) is distributing this material in Australia. It is directed at 'wholesale clients' as defined by Australian Corporations Act 2001.

IRS Circular 230 Prepared Materials Disclaimer: Barclays does not provide tax advice and nothing contained herein should be construed to be tax advice. Please be advised that any discussion of U.S. tax matters contained herein (including any attachments) (i) is not intended or written to be used, and cannot be used, by you for the purpose of avoiding U.S. tax-related penalties; and (ii) was written to support the promotion or marketing of the

transactions or other matters addressed herein. Accordingly, you should seek advice based on your particular circumstances from an independent tax advisor.

© Copyright Barclays Bank PLC (2015). All rights reserved. No part of this publication may be reproduced or redistributed in any manner without the prior written permission of Barclays. Barclays Bank PLC is registered in England No. 1026167. Registered office 1 Churchill Place, London, E14 5HP. Additional information regarding this publication will be furnished upon request.

